By the Numbers

The Current State of Real-World Evidence

Contributors: Vasco Pontinha, Virginia Commonwealth University, Richmond, VA, USA; Ana Gonçalves, Charité – Universitätsmedizin, Berlin, Germany; Jacinda Tran, University of Washington, Seattle, WA, USA; Shrey Gohil, University of Houston, Houston, TX, USA. Acknowledgement: We would like to thank Zeba Khan, RPh, PhD for her review and helpful comments.



1. Parody-Rua E, Rubio-Valera M, Guevara-Cuellar C, et al. Economic evaluations informed exclusively by real world data: a systematic review. Int J Environ Res Public Health. 2020;17(4).

2. Husereau D, Nason E, Ahuja T, Nikai E, Tsakonas E, Jacobs P. Use of real-world data sources for Canadian drug pricing and reimbursement decisions: stakeholder views and lessons for other countries. Int J Technol Assess Health Care. 2019;35(3):181-188.

3. Deloitte. RWE focus is shifting to R&D, early investments begin to pay off: how can others catch up? https://www2.deloitte.com/us/en/insights/industry/health-care/real-world-evidence-study.html. Accessed August 20, 2020.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now